These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7795140)

  • 41. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A.
    Globe DR; Cunningham WE; Andersen R; Dietrich SL; Curtis RG; Parish KL; Miller RT; Sanders NL; Kominski G;
    Haemophilia; 2003 May; 9(3):325-31. PubMed ID: 12694525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Quality of life of young patients with haemophilia in Europe].
    Bullinger M; Gringeri A; von Mackensen S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jun; 51(6):637-45. PubMed ID: 18481032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.
    Berger K; Schopohl D; Eheberg D; Auerswald G; Kurnik K; Schramm W
    Klin Padiatr; 2013 May; 225(3):152-8. PubMed ID: 23519749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimizing outcomes for patients with severe haemophilia A.
    Pipe SW; Valentino LA
    Haemophilia; 2007 Nov; 13 Suppl 4():1-16; quiz 3 p following 16. PubMed ID: 17822512
    [No Abstract]   [Full Text] [Related]  

  • 45. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States.
    Zhou ZY; Koerper MA; Johnson KA; Riske B; Baker JR; Ullman M; Curtis RG; Poon JL; Lou M; Nichol MB
    J Med Econ; 2015 Jun; 18(6):457-65. PubMed ID: 25660324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changing pattern of care of boys with haemophilia in western European centres.
    Chambost H; Ljung R;
    Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An economic model of haemophilia in Mexico.
    Martínez-Murillo C; Quintana S; Ambriz R; Benitez H; Berges A; Collazo J; Esparza A; Pompa T; Taboada C; Zavala S; Larochelle MR; Bentkover JD;
    Haemophilia; 2004 Jan; 10(1):9-17. PubMed ID: 14962215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is self-sufficiency financially viable and ethically justifiable?--legal aspects.
    Newdick C
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S37-8. PubMed ID: 7795137
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Economic evaluation: what are we looking for and how do we get there?
    Steen Carlsson K; Höjgård S; Lethagen S; Berntorp E; Lindgren B
    Haemophilia; 2004 Mar; 10 Suppl 1():44-9. PubMed ID: 14987248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cost of health care in children with haemophilia].
    González-Figueroa M; Canales-Muñoz JL; Aguayo-Alcaraz G; Zamora-Vázquez G
    Rev Med Inst Mex Seguro Soc; 2010; 48(2):199-204. PubMed ID: 20929625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data.
    Zhou ZY; Wu J; Baker J; Curtis R; Forsberg A; Huszti H; Koerper M; Lou M; Miller R; Parish K; Riske B; Shapiro A; Ullman M; Johnson K
    Haemophilia; 2011 Sep; 17(5):729-36. PubMed ID: 21689212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
    Walsh CE; Valentino LA
    Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adherence to prophylactic treatment in patients with haemophilia in Germany.
    Miesbach W; Kalnins W
    Haemophilia; 2016 Sep; 22(5):e367-74. PubMed ID: 27353213
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real-world study with 700 person-years.
    Vepsäläinen K; Riikonen P; Lassila R; Arola M; Huttunen P; Lähteenmäki P; Möttönen M; Selander T; Martikainen J
    Haemophilia; 2018 May; 24(3):436-444. PubMed ID: 29493848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.
    Pierce GF; Lusher JM; Brownstein AP; Goldsmith JC; Kessler CM
    JAMA; 1989 Jun; 261(23):3434-8. PubMed ID: 2498537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing options for treating haemophilia with inhibitors.
    Farrugia A; Hermans C; Franchini M
    Haemophilia; 2015 May; 21(3):307-309. PubMed ID: 25855015
    [No Abstract]   [Full Text] [Related]  

  • 59. Health economics of treating haemophilia A with inhibitors.
    Knight C
    Haemophilia; 2005 Nov; 11 Suppl 1():11-7. PubMed ID: 16219044
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
    Lange D; Lazerson J
    Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.